Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA7 | P43166 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | AGER | Q15109 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686748 | 1.00 | CA1 (0.62) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL8328277 | 1.00 | CA1 (0.62) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL397022 | 0.83 | CA1 (0.78) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL10493999 | 0.83 | CA1 (0.62) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL9870444 | 0.83 | CA1 (0.62) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL9870455 | 0.83 | CA1 (0.62) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL3325707 | 0.82 | TSHR (0.50) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL15939041 | 0.80 | CA1 (0.58) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL7153591 | 0.80 | CA1 (0.76) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL4898269 | 0.79 | TSHR (0.47) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101130538-A | Method for preparing (4R-Cis)-6-methylol-2, 2-dimethyl-1,3-dioxane-4-tert-butyl acetate | UNIV ZHEJIANG (CN) | 2008-02-27 | — | — | CN | claimed |
| CN-106382126-B | Supporting hydraulic device and its working method in a kind of high flexibility mortar working surface construction | 徐州工程学院 | 2019-02-26 | — | — | CN | disclosed |
| CN-106382126-A | Support hydraulic device in high-flexibility mortar working face construction and working method thereof | 徐州工程学院 | 2017-02-08 | — | — | CN | disclosed |
| WO-2014203045-A1 | A NOVEL, GREEN AND COST EFFECTIVE PROCESS FOR SYNTHESIS OF TERT-BUTYL (3R,5S)-6-OXO-3,5-DIHYDROXY-3,5-O-ISOPROPYLIDENE-HEXANOATE | LUPIN LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
| CN-101130538-A | Method for preparing (4R-Cis)-6-methylol-2, 2-dimethyl-1,3-dioxane-4-tert-butyl acetate | UNIV ZHEJIANG (CN) | 2008-02-27 | — | — | CN | disclosed |
| CN-1932031-A | Enzyme resolving process for preparing chiral beta-hydroxy nitrile | UNIV ZHEJIANG (CN) | 2007-03-21 | — | — | CN | disclosed |
| CN-1923792-A | (S) 6-arylmethyl-5-hydroxyl-3-oxy-hecanoic acid t-butyl ester and preparation method thereof | UNIV ZHEJIANG (CN) | 2007-03-07 | — | — | CN | disclosed |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040116330-A1 | Diagnosing or specifying a growth factor receptor expressed in cancer cells, and selectively inhibiting all or a part of the growth factor receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| CN-1487935-A | Improved water-soluble pharmaceutical compositions | ����ҩƷ��ҵ��ʽ���� | 2004-04-07 | — | — | CN | disclosed |
| US-6716863-B2 | TYROSINE KINASE INHIBITORS; ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040024035-A1 | Heterocyclic compounds, their production and use | TASAKA AKIHIRO (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1350792-A1 | MEDICINAL COMPOSITIONS IMPROVED IN SOLUBLITY IN WATER | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| EP-1350793-A1 | MEDICINAL COMPOSITIONS HAVING IMPROVED ABSORBABILITY | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| CN-1444582-A | Heterocyclic compound, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-09-24 | — | — | CN | disclosed |
| EP-1268473-A1 | OXAZOLE DERIVATIVES AND THEIR USES AS TYROSINE KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-20020173526-A1 | Heterocyclic compounds their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
| WO-2001077107-A1 | OXAZOLE DERIVATIVES AND THEIR USES AS TYROSINE KINASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024035-A1 | Heterocyclic compounds, their production and use | ABL1, ROS1, MAPK1 | CA1 2025/4885CA2 972/4885CA7 1085/4885 |
| US-20020173526-A1 | Heterocyclic compounds their production and use | ABL1, ROS1, MAPK1 | CA1 1865/4885CA2 845/4885CA7 1033/4885 |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | ERBB2, EGFR, ABCG2 | CA1 1778/4885CA2 729/4885CA7 532/4885 |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | EGFR, ERBB2, ERBB3 | CA1 2468/4885CA2 964/4885CA7 2543/4885 |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | EGFR, ERBB2, ERBB3 | CA1 674/4885CA2 271/4885CA7 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.